Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i> -mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Alfredo Budillon, Francesco Izzo et al.|Therapeutic Advances in Medical Oncology|2020Cited by 17
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II studyClaudia Cardone, Antonio Avallone, Anna Nappi et al.|ESMO Open|2023Cited by 6
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase 2 studyClaudia Cardone, Antonio Avallone, Alfonso De Stefano et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase 2 studyClaudia Cardone, Antonio Avallone, Alfonso De Stefano et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0